Thrombolytic in Medical Technology

Portable CT Increases Chance of Stroke Survival and Recovery

... to increase the number of patients to whom thrombolytic therapy can be administered," said the study's ... in the brain. Such strokes can be treated with thrombolytic therapy using a drug called tPA that dissolves ... number of stroke patients able to be treated with thrombolytic therapy within the three-hour window. ...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

... completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix ... animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which ...

Is PCI Safe, Effective After Clot-Busters for Heart Attack?

... PCI after treating patients with clot-busting drugs -- also known as thrombolytic or fibrinolytic agents -- offered no benefit and might even be harmful. Since then, however, thrombolytic medications have changed, stents are routinely used, and interventional ...

ImaRx Therapeutics Transitions Business Strategy

... the Company's first commercially available FDA approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ... formularies at approximately 700 acute care hospitals. Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive ...

Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion

... 3 SONOMA study provided further evidence that alfimeprase is an active thrombolytic which has the potential to dissolve clots quickly and rapidly restore ... that increasing the concentration can result in marked improvement in thrombolytic activity. Accordingly, we are resuming development of alfimeprase in CO to ...

Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series

... of CDT procedures. There were no reported bleeding complications related to the Trellis device in acute follow up and the dosage of thrombolytic drugs such as t-PA was reduced by 30% with use of the Trellis device compared to CDT. "Profound changes in the treatment paradigm for DVT are ...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

... programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; ...

Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women

... as a supplement in the June issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians (ACCP), Antithrombotic and thrombolytic Therapy: ACCP Evidence-Based Clinical Practice Guidelines, Eighth Edition was developed by an international panel of 90 experts and includes more ...

Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack

... 600,000 new attacks and 320,000 recurrent attacks. After an acute myocardial infarction, early and successful myocardial reperfusion with the use of thrombolytic therapy such as tissue plasminogen activator (tPA) or primary percutaneous coronary intervention (PCI) is the most effective strategy for reducing ...

CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors

... patients up to 24 hours after symptom onset and another which adds NeuroFlo treatment to the current standard of care -- intravenous delivery of the thrombolytic drug, t-PA. CoAxia, Inc. is a venture-backed, privately held, development-stage company focused on providing perfusion augmentation therapies that ...

ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)

... programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases such as acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with ...

The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor

... 2005;20:15-7 3. Geerts WH, Pineo GF, Heit JA et al. Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and thrombolytic Therapy. Chest 2004;126:338-400 ...

New Information on the Potential of Plasmin Shared at ISTH Congress

... is derived from human plasma, is a unique locally-acting, fibrin-specific thrombolytic that can be infused directly into a clot via a catheter using minimally ... unmet clinical needs." Satellite Symposium: "Potential for Better thrombolytic Therapy: Is Plasmin the Answer?" Talecris also hosted a Satellite ...

Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session

... for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that ...

Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting

... for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that ...

Nuvelo Announces Publication of NU206 Study Results in Gastroenterology

... for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that ...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

... for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex ...